Spherix Announces the Closing of CBM BioPharma Transaction
(WorldNews Health)

NEW YORK, Dec. 10, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has closed the CBM BioPharma, Inc. transaction and is working to develop these cancer drugs. Building on its successful investment in Hoth Therapeutics, Inc., Spherix now owns a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The Spherix platform contains patented technology from leading universities and researchers and we seek to develop our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas at Austinand Wake Forest University. The Company`s diverse pipeline of therapeutics includes therapies for pancreatic...